POMDOCTOR LIMITED American Depositary Shares (POM) - Cash Flow Conversion Efficiency

Latest as of March 2020: 0.033x

Based on the latest financial reports, POMDOCTOR LIMITED American Depositary Shares (POM) has a cash flow conversion efficiency ratio of 0.033x as of March 2020. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.08 Billion) by net assets ($32.48 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see POMDOCTOR LIMITED American Depositary Sh (POM) total market value for the company's overall valuation and market capitalisation.

POMDOCTOR LIMITED American Depositary Shares - Cash Flow Conversion Efficiency Trend (2003–2025)

This chart illustrates how POMDOCTOR LIMITED American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.

POMDOCTOR LIMITED American Depositary Shares Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of POMDOCTOR LIMITED American Depositary Shares ranked by their cash flow conversion efficiency. Explore POMDOCTOR LIMITED American Depositary Sh cash earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
GoHealth, Inc.
NASDAQ:GOCOQ
-0.055x
Betacom S.A.
WAR:BCM
0.199x
Biofil Chemicals & Pharmaceuticals Limited
NSE:BIOFILCHEM
-0.167x
Ansal Properties & Infrastructure Limited
NSE:ANSALAPI
-0.110x
Enquest Plc
LSE:ENQ
0.453x
Dlaboratory Sweden AB
ST:DLAB
0.162x
Boqii Holding Limited
NYSE:BQ
0.002x
Clearmind Medicine Inc. Common Shares
NASDAQ:CMND
-0.253x

Annual Cash Flow Conversion Efficiency for POMDOCTOR LIMITED American Depositary Shares (2003–2025)

The table below shows the annual cash flow conversion efficiency of POMDOCTOR LIMITED American Depositary Shares from 2003 to 2025. View POM stock price and chart for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $-481.30 Million $-148.48 Million 0.308x +3906.13%
2024-12-31 $-2.09 Billion $-16.13 Million 0.008x -67.02%
2023-12-31 $-1.96 Billion $-45.80 Million 0.023x +101.27%
2022-12-31 $-1.90 Billion $-22.02 Million 0.012x +31.49%
2021-12-31 $-1.78 Billion $-15.68 Million 0.009x -92.16%
2020-12-31 $-309.35 Million $-34.80 Million 0.112x +332.60%
2019-12-31 $3.27 Billion $85.00 Million 0.026x -90.75%
2018-12-31 $30.76 Billion $8.64 Billion 0.281x +12.15%
2017-12-31 $29.86 Billion $7.48 Billion 0.251x -23.35%
2016-12-31 $25.84 Billion $8.45 Billion 0.327x +53.61%
2015-12-31 $4.41 Billion $939.00 Million 0.213x +7.69%
2014-12-31 $4.32 Billion $854.00 Million 0.198x +71.55%
2013-12-31 $4.32 Billion $497.00 Million 0.115x -13.50%
2012-12-31 $4.45 Billion $592.00 Million 0.133x -15.84%
2011-12-31 $4.34 Billion $686.00 Million 0.158x +88.51%
2010-12-31 $703.00 Million $59.00 Million 0.084x +1966.11%
2009-12-31 $10.83 Billion $44.00 Million 0.004x -65.59%
2008-12-31 $11.10 Billion $131.00 Million 0.012x -3.54%
2007-12-31 $10.38 Billion $127.00 Million 0.012x +77.75%
2006-12-31 $9.88 Billion $68.00 Million 0.007x +85.86%
2005-12-31 $9.18 Billion $34.00 Million 0.004x -46.21%
2004-12-31 $8.28 Billion $57.00 Million 0.007x -66.55%
2003-12-31 $8.06 Billion $166.00 Million 0.021x --

About POMDOCTOR LIMITED American Depositary Shares

NASDAQ:POM USA Pharmaceutical Retailers
Market Cap
$5.62 Million
Market Cap Rank
#28439 Global
#5798 in USA
Share Price
$0.83
Change (1 day)
-4.55%
52-Week Range
$0.07 - $6.09
All Time High
$6.09
About

Pomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company in involv… Read more